OriCiro Genomics is a genome technology company offering innovative products and services for synthetic biology. The company has developed cell-free technologies of large DNA assembly and amplification that enable an efficient synthesis of genome-scale DNA aiming at replacing conventional cell-based cloning.
OriCiro was established in December 2018, located in Tokyo, and raised $3.6M in Series A in March 2019 from UTEC, a Tokyo-based VC. Company’s mission is to create a better Bioeconomy with innovate genome technologies.
We offer reagent kits for academia research, as well as opportunities of technology licensing to, and co-development with corporate partners from the pharma, diagnostics, agriculture and industrial biotech sectors.